Plasma Derived Medicine Market Set to Witness Significant Growth by 2025-2032 | CSL Behring, Takeda Pharmaceutical Company Limited, Grifols, S.A., Octapharma AG

The plasma derived medicine industry is witnessing robust developments driven by increasing prevalence of immune disorders, chronic diseases, and rising demand for advanced biologics. Innovations in plasma fractionation technologies coupled with an expanding healthcare infrastructure are facilitating enhanced production capabilities and improved patient access worldwide. Such dynamics shape the comprehensive market landscape and reflect evolving industry trends focused on therapeutic efficacy and safety. The Global Plasma Derived Medicine Market size is estimated to be valued at USD 19.87 billion in 2025 and is expected to reach USD 32.77 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032. This market forecast underscores significant growth opportunities and evolving market share across major geographies, supported by progressive regulatory frameworks and increasing plasma donation drives.

Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/4929

➤Analyst Opinion

● The rising demand for immunoglobulins and albumin continues to be a critical supply-side indicator driving plasma derived medicine market revenue growth. In 2024, the global immunoglobulin consumption increased by 12% owing to escalating use in autoimmune and immunodeficiency therapies, exemplified by the U.S. market reporting a year-over-year volume increase of 1.5 million liters of plasma collected. This surge directly impacts industry size and market share, evidencing heightened manufacturing capacities among leading plasma companies.

● Pricing dynamics globally reflect nuanced regional disparities; while North America maintains premium pricing due to stringent quality standards, Asia Pacific markets have exhibited a 9% average price decline in 2024, driven by governmental subsidies and localized production. This demand-side variation affects market growth strategies, optimizing cost-benefit frameworks and expanding market reach particularly in emerging economies.

● Micro-indicators such as technological advancements in pathogen reduction and cold chain logistics are reshaping product portfolios. For example, in 2025, over 30% of plasma products in Europe incorporated novel virus clearance technologies, elevating product safety and consumer confidence, which ultimately augment market revenue and support competitive market players.

● Import-export trade flows also provide valuable market insights; shipments of plasma-derived medicinal products from Europe to Asia increased by 18% in 2024 due to demand fluctuations and regional supply constraints. These trends highlight the growing complexity of global supply chains and underscore the necessity of agile market analysis to adapt to fluctuating market dynamics.

➤Market Taxonomy and Regional coverage of Report

● Comprehensive Taxonomy of the Report:
» By Product Type: Immunoglobulin, Albumin, Coagulation Factors, Plasma Derivatives, and Others.
» By Application: Immune Deficiency Diseases, Hemophilia, Autoimmune Diseases, Trauma/Burns, and Others.
» By End User: Hospitals, Clinics, Diagnostic Centers, and Ambulatory Services.

● Regional and Country Analysis:

» North America: U.S. and Canada
» Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
» Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
» Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
» Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA.

Purchase Now Up to 25% Discount on This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/4929

➤Leading Companies of the Market

● CSL Behring
● Takeda Pharmaceutical Company Limited
● Grifols, S.A.
● Octapharma AG
● Kedrion Biopharma
● LFB S.A.
● ADMA Biologics, Inc.
● Bio Products Laboratory Ltd.
● China Biologic Products Holdings, Inc.
● Shanghai RAAS Blood Products Co., Ltd.
● HemaCare Corporation
● Sanquin Blood Supply Foundation
● Biotest AG
● Emergent BioSolutions Inc.
● Medac GmbH
● Scripps Laboratories
● Fresenius Kabi AG
● Kamada Pharmaceuticals

Several leading companies have strategically expanded their plasma collection networks and enhanced manufacturing capacities. For instance, Takeda implemented a multi-year initiative boosting plasma donation centers across North America, leading to a 15% increase in plasma supply as reported in Q1 2025. Similarly, CSL Behring adopted vertical integration models with advanced fractionation technology investments, resulting in improved cost efficiencies and a 10% rise in market share in 2024. Grifols diversified its product portfolio by investing in novel coagulation factors, strategically positioning itself in emerging therapeutic segments and elevating competitive advantage.

➤Key Growth Drivers Fuelling Market Expansion

Increasing prevalence of chronic diseases such as hemophilia and immune deficiencies is driving the demand for plasma derived medicines globally. According to WHO data from 2024, hemophilia patients receiving treatment increased by 8%, fueling market growth. Expanded plasma collection infrastructure in emerging economies is critical, with India and China reporting a combined 20% rise in plasma donations in 2025, enhancing domestic manufacturing capabilities. Regulatory approvals facilitating faster market entry for new plasma-derived therapeutics are pivotal growth enablers; for example, the U.S. FDA approved three new immunoglobulin product variants in 2024, accelerating product availability. The rising trend of personalized medicine and tailored therapies is increasing focus on plasma derivative innovation, with R&D investments surpassing USD 500 million globally in 2024, indicating strong market scope and business growth potential.

➤Key Reasons for Buying the Plasma Derived Medicine Report

✦ Comprehensive analysis of the changing competitive landscape
✦ Assists in decision-making processes for the businesses along with detailed strategic planning methodologies
✦ The report offers forecast data and an assessment of the Plasma Derived Medicine
✦ Helps in understanding the key product segments and their estimated growth rate
✦ In-depth analysis of market drivers, restraints, trends, and opportunities
✦ Comprehensive regional analysis of the Plasma Derived Medicine
✦ Extensive profiling of the key stakeholders of the business sphere
✦ Detailed analysis of the factors influencing the growth of the Plasma Derived Medicine

Purchase Now Up to 25% Discount on This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/4929

➤ Emerging Trends and Market Shift

The plasma derived medicine market is experiencing a paradigm shift with emerging trends such as increased adoption of recombinant technologies supplementing traditional plasma derived products. The rising integration of artificial intelligence and automation in plasma fractionation processes is reducing turnaround times and quality inconsistencies, as reflected in a 2024 report citing a 25% reduction in manufacturing cycle times in Europe. Moreover, the increased focus on sustainability and ethical plasma sourcing is prompting market players to innovate plasma collection practices, aligning with global healthcare sustainability goals. Geographic shifts show Asia Pacific emerging as a critical market growth center due to rising healthcare investments and government plasma donation drives, accounting for 18% of market revenue in 2025.

➤High-Impact Market Opportunities by Segment and Region

The immunoglobulin segment presents a substantial growth opportunity, propelled by expanding therapeutic applications in autoimmune diseases and primary immune deficiencies. Market revenues in this segment are expected to grow at a CAGR exceeding 8% through 2032 due to unmet clinical needs and enhanced clinical guidelines. Albumin products, driven by application in trauma and burns management, are witnessing increased uptake in hospital settings, contributing significantly to market revenue expansion in North America. Regionally, Asia Pacific offers high-impact growth opportunities propelled by increasing plasma donation campaigns and augmenting industrial capacity, with China alone projected to contribute over USD 3 billion in market revenue by 2028, underscoring a significant market expansion prospect.

❓ Frequently Asked Questions

1. Who are the dominant players in the Plasma Derived Medicine market?
Leading market companies include CSL Behring, Takeda Pharmaceutical, Grifols, and Octapharma AG, among others. These companies dominate through strategic acquisitions, capacity expansions, and continuous product innovation.

2. What will be the size of the Plasma Derived Medicine market in the coming years?
The market size is projected to increase from USD 19.87 billion in 2025 to USD 32.77 billion by 2032, representing a CAGR of 7.4%, driven by rising demand across therapeutic applications globally.

3. Which end-user industry has the largest growth opportunity?
Hospitals and specialized clinics treating immune deficiencies and hemophilia possess the largest growth opportunities, accounting for a significant share of market revenue due to increased patient volume and advanced treatment protocols.

4. How will market development trends evolve over the next five years?
Market trends will focus on advanced plasma collection technologies, recombinant product integration, regional plasma supply decentralization, and enhanced regulatory frameworks to ensure product safety and accessibility.

5. What is the nature of the competitive landscape and challenges in the Plasma Derived Medicine market?
The competitive landscape is characterized by consolidation and innovation, while challenges include plasma supply shortages, stringent regulatory compliance, and market restraints imposed by donor variability and infectious disease screening requirements.

6. What go-to-market strategies are commonly adopted in the Plasma Derived Medicine market?
Market companies frequently adopt strategies such as expanding plasma collection centers, investing in advanced fractionation technology, pursuing partnerships for global distribution, and engaging in targeted R&D to meet evolving therapeutic demands.

✍️ PR Authored By:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report.

About Us:

With a proven excellence in market research, Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

☎️ Contact Us:

533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
United States of America: + 12524771362
United Kingdom: UK Number: +442039578553
Australia: +61-8-7924-7805
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com

This release was published on openPR.